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African Americans have a greater risk of cardiovascular
disease (CVD) than Caucasians in early chronic kidney
disease; however, limited data describe racial and ethnic
differences in the risk of incident myocardial infarction
(MI) among patients with end-stage renal disease (ESRD).
We conducted a prospective, observational cohort study
among 271 102 incident dialysis patients receiving renal
replacement therapy enrolled in the United States Renal Data
System (USRDS) for whom Medicare was the primary insurer
between 1995 and 2000. The incidence and risk of any MI
(non-fatal or fatal) estimated by Cox proportional hazards
models was the primary outcome of interest. Of those with
prevalent CVD at baseline (118 708), 14 849 had an incident
non-fatal MI compared with 9926 events for those without
prevalent CVD (152 394). Patients with prevalent CVD had
higher crude rates of combined fatal and non-fatal MI
(99.3/1000 person-years vs 42.9/1000 person-years)
compared with those without prevalent CVD. Among those
with prevalent CVD, African Americans (adjusted relative risk
(aRR)¼ 0.65, 95% confidence interval (CI):0.62–0.68), Asian
Americans (aRR¼ 0.74, 95% CI: 0.66–0.83), and Hispanics
(aRR¼ 0.72, 95% CI: 0.68–0.77) were 26–35% less likely to
have an incident MI compared to Caucasians. Similarly,
among those without prevalent CVD, racial/ethnic minorities
were 26–42% less likely to have an incident MI compared to
Caucasians. We conclude that in a national setting where
comparable access to dialysis and associated medical care,
exist, racial/ethnic minorities were found to have a lower risk
of non-fatal and fatal MI than Caucasians.
Kidney International (2006) 69, 1691–1698. doi:10.1038/sj.ki.5000346;
published online 5 April 2006
KEYWORDS: race; ESRD; transplant; dialysis; mortality; myocardial infarction
Cardiovascular disease (CVD) is the primary cause of death in
the general population and in patients with end-stage renal
disease (ESRD).1 Patients on dialysis are reported to have a
30-fold greater risk of CVD associated mortality than the
general population.2 Among individuals with chronic renal
insufficiency, racial and ethnic (racial/ethnic) minorities have
been found to have higher rates of CVD than Caucasians,3 but
limited data exist that compare racial and ethnic differences in
incident myocardial infarction (MI) among those with ESRD.
Utilizing data from the United States Renal Data System
(USRDS), Trespalacios et al.4 found that African Americans
were less likely to have prevalent coronary heart disease than
Caucasians, but racial/ethnic differences in admissions for
acute coronary syndrome or MI were not assessed. Also,
racial/ethnic differences in the risk of atherosclerotic disease
(cardiovascular, stroke, peripheral vascular disease) were
assessed recently, but risk of MI was not assessed separately.5
Initiated in 1972, the ESRD Medicare entitlement
program has allowed for governmental reimbursement for
initiation and continuation of dialysis across the United
States. In that regard, the Medicare program was one of the
first nationwide programs that offered a form of national
health insurance coverage. We hypothesized that in the
setting where medical insurance access is comparable, racial/
ethnic differences in incident fatal and non-fatal MI would be
minimized if access to care is the primary factor accounting
for racial/ethnic disparities in incident MI. Using data from
the USRDS, which records data from all patients who initiate
dialysis in the United States, we sought to evaluate racial/
ethnic differences in incident non-fatal and fatal MI in the
setting where comparable insurance coverage for renal replace-
ment therapy, physician reimbursement, and hospitalizations
exists for all subjects.
RESULTS
Data were available for 506 922 ESRD patients who initia-
ted renal replacement therapy between January 1, 1995 and
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December 31, 2000. Of these, 201 870 (39.8%) patients were
not eligible for Medicare insurance coverage within 90 days of
starting renal replacement therapy and were excluded. Of the
remaining patients, 33 950 (6.7%) were further excluded owing
to an incomplete medical evidence form, before transplant or
MI, or for not having Medicare coverage before December 31,
2000, which resulted in 271 102 patients identified for the
current analysis. Of those identified, 118 708 (43.8%) had
prevalent CVD, whereas 152 394 (56.2%) did not have
prevalent CVD. Overall, 52.0% were male, 52.1% were
Caucasian, 31.6% were African American, 3.0% were Asian
American, and 11.5% were Hispanic. Diabetes (45.3%) was the
primary cause of ESRD, followed by hypertension (28.1%) and
glomerulonephritis (9.0%). On average, patients were anemic
(hemoglobin 9.571.8 g/dl), elderly (mean age 63.5715.3
years), slightly malnourished (albumin 3.270.7 g/dl), and had
low creatinine clearances (3.076.0 ml/min) at the initiation of
dialysis. Prevalent erythropoietin (EPO) use was observed in
approximately a quarter of all patients (25.4%). Those of other
race/ethnicity (n¼ 4679; 1.7%) were younger and more likely
to have diabetes compared to the remaining groups.
Among those with prevalent CVD (Table 1), the majority
were Caucasian (60.0%), followed by African Americans
(25.6%), Hispanics (10.1%), Asian Americans (2.57%), and
those of other race/ethnicity (1.69%). African Americans,
Hispanics, and Asians were more likely to be female, were
more likely to be less than 60 years of age, and were more
likely to have diabetes than Caucasians. Those of other race/
ethnicity (79.0%) contained the greatest proportion of those
with diabetes as the underlying renal disease. EPO use before
initiation of dialysis was less likely for African Americans and
Hispanics compared with Caucasians and Asians, although
baseline laboratory values were similar among all groups
within the cohort.
Compared to those with prevalent CVD, those without
prevalent CVD (Table 1) had greater proportions of African
Americans (36.3%), Hispanics (12.6%), Asian Americans
(3.41%), and those of other race/ethnicity (1.75%) than
Caucasians (45.9%). Similar to what was found among those
with prevalent CVD, diabetes was the primary cause of ESRD
and greatest for those of other race/ethnicity, Hispanics,
Asians, and African Americans (in that order) compared to
Caucasians. Pre-dialysis EPO use was lowest for African
Americans compared to other racial/ethnic groups, and
African Americans were, on average, the youngest group to
initiate renal replacement therapy. Hemoglobin levels were
lower for those without prevalent CVD compared to those
with prevalent CVD, and African Americans without
prevalent CVD had the lowest hemoglobin level of all groups
(9.0971.83%). On average, baseline serum creatinine levels
were higher for racial/ethnic minority groups than Cauca-
sians in both those with and without prevalent CVD, whereas
African Americans started dialysis with the highest average
baseline serum creatinine. Also, racial and ethnic minorities
of both CVD groups had the lowest baseline serum albumin
levels compared to Caucasians.
Unadjusted MI event rates were approximately two-fold
greater among those with prevalent CVD compared to
those without (Table 2), and highest among those less than
45 years of age (2.8-fold greater). Among those with
prevalent CVD, greater non-fatal and combined MI event
rates were observed for men, Caucasians, the elderly, those
with hypertension as the primary cause of ESRD, and for
those without pre-dialysis EPO use. Those 75 years and older,
Caucasians, and those unable to ambulate had both the
highest overall non-fatal and highest overall combined MI
event rates. Similarly, among those without prevalent
CVD, the elderly, Caucasians, those with diabetes, and those
unable to ambulate were more likely to have both non-fatal
and combined MI, although rates were similar between men
and women and between those with and without predialysis
EPO use.
We determined estimates of the adjusted relative risk
(aRR) of incident non-fatal and combined MI separately for
subgroups defined by prevalent CVD status (Table 3). Risk
estimates were similar for models of non-fatal MI compared
with combined MI; thus, results are shown only for the
combined end point. All estimates were adjusted for age at
the start of renal replacement therapy, gender, primary cause
of ESRD, dialysis modality (hemodialysis, peritoneal dialysis,
and transplant) and transplant waiting list status as well
as available baseline laboratory values. Final models were
restricted to 81 106 (prevalent) and 100 998 (non-prevalent
CVD) subjects owing to missing laboratory values, although
these restrictions changed the point estimates of the results
minimally.
Among those with prevalent CVD, African Americans
were estimated to have the lowest risk of combined MI
(aRR¼ 0.65, 95% confidence interval (CI): (0.62, 0.68))
compared to Caucasians. Asian Americans with prevalent
CVD had a 26% decreased risk (aRR¼ 0.74, 95% CI: (0.66,
0.83)), whereas Hispanics (aRR¼ 0.72, 95% CI: (0.68, 0.77))
had lower adjusted risk of incident non-fatal and fatal MI
compared to Caucasians. With respect to other known risk
factors, among those with prevalent CVD, increasing age,
male gender, and renal failure owing to diabetic nephropathy
were all independently associated with a greater risk of
combined MI. Compared to patients on hemodialysis, those
on peritoneal dialysis had a 2% lower risk of combined MI
(aRR¼ 0.98, 95% CI: (0.93, 1.02)), whereas those on the
wait list were 32% less likely to have an event compared to
those not wait-listed on hemodialysis. Additionally, when
other causes of cardiovascular death were added to the
combined end-point, modest changes to the point estimates
were found (data not shown).
Similarly, among those without prevalent CVD, African
Americans had a 33% lower risk of combined MI (aRR¼
0.67, 95% CI: (0.64, 0.71)) compared to Caucasians. Asian
Americans without prevalent CVD had 28% lower risk
(aRR¼ 0.72, 95% CI: (0.63, 0.81)), whereas Hispanics had a
35% lower adjusted risk of combined MI event (aRR¼ 0.65,
95% CI: (0.60, 0.70)), compared to Caucasians (Table 3).
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Compared to patients on hemodialysis, those on peritoneal
dialysis without prevalent CVD had an insignificantly
elevated relative risk of combined MI (aRR non-prevalent
CVD 1.06, 95% CI: (0.99, 1.15)). Additionally, those on the
waiting list were 32% less likely to have an event compared to
those not wait-listed on hemodialysis, whereas those who
received a transplant were 69% less likely to have an event
compared to those on hemodialysis.
DISCUSSION
Among a national cohort of patients who had Medicare as
their primary insurance, prevalent CVD was a significant risk
Table 1 | Baseline demographics of USRDS Medicare cohort
Overall Caucasian African American Asian American Hispanic Other
Prevalent CVD
Total 118 708 71 186 (60.0%) 30 452 (25.6%) 3051 (2.57%) 11 997 (10.1%) 2007 (1.69%)
Female 57 904 (48.8%) 31 604 (44.4%) 17 550 (57.6%) 1575 (51.6%) 6056 (50.5%) 1114 (55.5%)
Age group
Less than 45 years 5996 (5.05%) 2297 (3.23%) 2713 (8.91%) 147 (4.82%) 706 (5.88%) 131 (6.53%)
45–59 years 20 606 (17.4%) 8807 (12.4%) 7540 (24.8%) 446 (14.6%) 3168 (26.4%) 643 (32.0%)
60–74 years 55 049 (46.4%) 33 366 (46.9%) 13 599 (44.7%) 1372 (45.0%) 5760 (48.0%) 945 (47.1%)
75 years and older 37 057 (31.2%) 26 716 (37.5%) 6600 (21.7%) 1086 (35.6%) 2363 (19.7%) 288 (14.4%)
Cause of ESRD
Diabetes 62 712 (52.8%) 33 528 (47.1%) 16 720 (54.9%) 1832 (60.0%) 9036 (75.3%) 1586 (79.0%)
Hypertension 34 130 (28.8%) 21 649 (30.4%) 9784 (32.1%) 730 (23.9%) 1755 (14.6%) 211 (10.5%)
Glomerulonephritis 6996 (5.89%) 4908 (6.89%) 1329 (4.36%) 230 (7.54%) 444 (3.7%) 85 (4.24%)
Other 14 870 (12.5%) 11 101 (15.6%) 2619 (8.6%) 259 (8.49%) 762 (6.35%) 125 (6.23%)
Baseline lab values (N (%) or mean (s.d.))a
Inability to ambulate 7413 (6.24%) 4328 (6.08%) 2085 (6.85%) 163 (5.34%) 726 (6.05%) 109 (5.43%)
EPO use predialysis 31 030 (26.1%) 19 910 (28.0%) 6929 (22.8%) 940 (30.8%) 2758 (23.0%) 489 (24.4%)
Age at start 68.1 (12.2) 70.4 (11.1) 64.3 (13.3) 69.3 (12.5) 64.7 (12.0) 62.6 (11.6)
Albumin (g/dl) 3.14 (0.63) 3.18 (0.61) 3.1 (0.63) 3.05 (0.64) 3.03 (0.63) 2.91 (0.64)
Hemoglobin (g/dl) 9.65 (1.68) 9.84 (1.62) 9.25 (1.75) 9.65 (1.75) 9.53 (1.68) 9.39 (1.65)
BUN (mg/dl) 91.1 (32.8) 93.0 (33.2) 88.1 (32.0) 91.4 (32.8) 87.6 (31.7) 87.7 (31.2)
Creatinine clearance (ml/min) 3.52 (6.41) 3.72 (6.66) 3.04 (5.98) 2.99 (5.48) 3.72 (6.16) 3.17 (5.78)
Serum creatinine (mg/dl) 6.99 (3.02) 6.53 (2.63) 7.98 (3.52) 7.38 (3.17) 7.08 (3.12) 7.17 (3.13)
Height (cm) 167.0 (12.9) 168.0 (12.7) 167.0 (12.9) 159.0 (11.6) 161.0 (12.8) 165.0 (12.8)
Weight (kg) 73.5 (19.2) 73.7 (18.6) 76.1 (21.0) 59.9 (16.3) 69.1 (17.0) 72.8 (18.5)
No prevalent CVD
Total 152 394 69 946 (45.9%) 55 330 (36.3%) 5191 (3.41%) 19 241 (12.6%) 2672 (1.75%)
Female 72 201 (47.4%) 31 692 (45.3%) 27 776 (50.2%) 2619 (50.5%) 8703 (45.2%) 1405 (52.6%)
Age group
Less than 45 years 31 858 (20.9%) 11 104 (15.9%) 14 833 (26.8%) 994 (19.2%) 4362 (22.7%) 560 (21.0%)
45–59 years 36 633 (24.0%) 12 968 (18.5%) 15 628 (28.2%) 1166 (22.5%) 5882 (30.6%) 986 (36.9%)
60–74 years 54 546 (35.8%) 27 374 (39.1%) 17 604 (31.8%) 1909 (36.8%) 6775 (35.2%) 880 (32.9%)
75 years and older 29 357 (19.3%) 18 500 (26.4%) 7265 (13.1%) 1122 (21.6%) 2222 (11.6%) 246 (9.21%)
Cause of ESRD
Diabetes 60 207 (39.5%) 24 651 (35.2%) 20 821 (37.6%) 2164 (41.7%) 10 820 (56.2%) 1745 (65.3%)
Hypertension 42 027 (27.6%) 16 633 (23.8%) 20 326 (36.7%) 1333 (25.7%) 3436 (17.9%) 296 (11.1%)
Glomerulonephritis 17 346 (11.4%) 9167 (13.1%) 4940 (8.93%) 889 (17.1%) 2045 (10.6%) 302 (11.3%)
Other 32 813 (21.5%) 19 495 (27.9%) 9242 (16.7%) 805 (15.5%) 2940 (15.3%) 329 (12.3%)
Baseline lab values (N (%) or mean (s.d.))b
Inability to ambulate 4175 (2.74%) 1948 (2.79%) 1567 (2.83%) 100 (1.93%) 487 (2.53%) 72 (2.69%)
EPO use predialysis 37 921 (24.9%) 20 084 (28.7%) 11 444 (20.7%) 1576 (30.4%) 4212 (21.9%) 601 (22.5%)
Age at start 59.8 (16.4) 63.5 (16.0) 56.3 (16.2) 60.9 (16.6) 56.9 (15.6) 56.3 (14.4)
Albumin (g/dl) 3.2 (0.69) 3.26 (0.67) 3.15 (0.71) 3.2 (0.67) 3.15 (0.69) 3.01 (0.7)
Hemoglobin (g/dl) 9.44 (1.81) 9.76 (1.75) 9.09 (1.83) 9.5 (1.88) 9.35 (1.79) 9.28 (1.78)
BUN (mg/dl) 89.7 (34.0) 90.0 (33.8) 89.4 (34.3) 92.1 (34.9) 89.7 (33.5) 85.4 (32.1)
Creatinine clearance (ml/min) 2.56 (5.65) 2.9 (5.88) 2.15 (5.39) 2.22 (5.03) 2.63 (5.64) 2.34 (4.95)
Serum creatinine (mg/dl) 8.73 (4.05) 7.82 (3.36) 9.87 (4.54) 8.86 (4.0) 8.76 (4.07) 8.55 (3.82)
Height (cm) 167.0 (13.3) 168.0 (12.8) 168.0 (13.4) 160.0 (12.1) 163.0 (13.4) 165.0 (13.0)
Weight (kg) 73.9 (19.9) 73.9 (19.4) 76.5 (20.9) 60.5 (16.5) 70.2 (17.7) 74.4 (19.6)
BUN, blood urea nitrogen; CVD, cardiovascular disease; EPO, erythropoietin; ESRD, end-stage renal disease; s.d., standard deviation; USRDS, United States Renal Data System.
aPrevalent CVD baseline lab missing values: inability to ambulate (0.03%), hemoglobin (12.2%), albumin (21.4%), BUN (5.89%), and EPO use (0.06%).
bNo prevalent CVD baseline lab missing values: hemoglobin (13.0%), albumin (23.2%), BUN (7.36%), and EPO use (0.06%).
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Table 2 | Non-fatal and combined MI event rates (95% CI)
N, total N, non-fatal MI N, combined MI
Non-fatal MI rate
(per 1000) (95% CI)
Combined MI rate
(per 1000) (95% CI)a
Prevalent CVD
Total 118 708 14 849 18 349 80.3 (79.0, 81.6) 99.3 (97.8, 100.7)
Gender
Men 60 804 7782 9662 83.5 (81.7, 85.4) 103.7 (101.6, 105.8)
Women 57 904 7067 8687 77.1 (75.3, 78.9) 94.7 (92.8, 96.7)
Age group
Less than 45 years 5996 385 483 31.0 (28.0, 34.2) 38.9 (35.5, 42.4)
45–59 years 20 606 2026 2573 54.0 (51.7, 56.4) 68.6 (66.0, 71.3)
60–74 years 55 049 7444 9180 84.9 (83.0, 86.9) 104.8 (102.6, 106.9)
75 years and older 37 057 4994 6113 105.6 (102.7, 108.5) 129.2 (126.0, 132.5)
Race
Caucasian 71 186 9921 12 139 98.3 (96.4, 100.3) 120.3 (118.2, 122.5)
African American 30 452 3046 3775 55.5 (53.5, 57.5) 68.7 (66.6, 70.9)
Asian American 3051 360 473 72.4 (65.1, 80.0) 95.1 (86.5, 103.7)
Hispanic 11 997 1326 1698 64.7 (61.2, 68.2) 82.8 (78.9, 86.7)
Other 2007 193 261 54.6 (47.1, 62.5) 73.8 (64.8, 82.7)
Cause of ESRD
Diabetes 62 712 7924 9901 80.3 (78.6, 82.1) 100.4 (98.4, 102.3)
Hypertension 34 130 4511 5522 86.0 (83.5, 88.5) 105.3 (102.5, 108.1)
Glomerulonephritis 6996 776 959 62.3 (58.0, 66.7) 77.0 (72.1, 81.8)
Other 14 870 1638 1967 77.0 (73.3, 80.7) 92.4 (88.3, 96.5)
Ability to ambulate 111 255 14 026 17 273 80.0 (78.7, 81.3) 98.5 (97.0, 100.0)
Inability to ambulate 7413 817 1070 87.2 (81.3, 93.2) 114.2 (107.3, 121.0)
No EPO predialysis 87 610 11 207 13 832 81.8 (80.3, 83.4) 101.0 (99.3, 102.7)
EPO predialysis 31 030 3638 4511 76.1 (73.6, 78.6) 94.3 (91.6, 97.1)
No Prevalent CVD
Total 152 394 9926 12 475 34.2 (33.5, 34.8) 42.9 (42.2, 43.7)
Gender
Men 80 193 5099 6485 33.5 (32.6, 34.4) 42.6 (41.6, 43.6)
Women 72 201 4827 5990 34.9 (33.9, 35.9) 43.3 (42.2, 44.4)
Age group
Less than 45 years 31 858 761 968 10.6 (9.9, 11.4) 13.5 (12.7, 14.4)
45–59 years 36 633 1986 2523 27.1 (25.9, 28.3) 34.4 (33.0, 35.7)
60–74 years 54 546 4594 5726 45.4 (44.1, 46.7) 56.6 (55.1, 58.0)
75 years and older 29 357 2585 3258 58.4 (56.2, 60.7) 73.6 (71.1, 76.2)
Race
Caucasian 69 946 5391 6687 43.8 (42.6, 44.9) 54.3 (53.0, 55.6)
African American 55 330 3015 3835 26.7 (25.7, 27.6) 33.9 (32.8, 35.0)
Asian American 5191 332 410 33.6 (30.1, 37.4) 41.5 (37.5, 45.6)
Hispanic 19 241 1051 1364 27.2 (25.6, 28.8) 35.3 (33.4, 37.1)
Other 2672 135 177 23.9 (20.1, 28.1) 31.4 (26.8, 36.0)
Cause of ESRD
Diabetes 60 207 4848 6121 43.8 (42.6, 45.0) 55.3 (53.9, 56.7)
Hypertension 42 027 2903 3632 35.8 (34.6, 37.2) 44.8 (43.4, 46.3)
Glomerulonephritis 17 346 739 921 19.5 (18.2, 21.0) 24.4 (22.8, 25.9)
Other 32 813 1436 1801 23.6 (22.4, 24.8) 29.6 (28.2, 30.9)
Ability to ambulate 148 219 9661 12 125 34.0 (33.3, 34.7) 42.7 (41.9, 43.4)
Inability to ambulate 4175 265 350 41.8 (36.9, 46.9) 55.1 (49.4, 60.9)
No EPO predialysis 114 385 7426 9397 33.6 (32.8, 34.4) 42.5 (41.6, 43.4)
EPO predialysis 37 921 2498 3075 36.1 (34.7, 37.5) 44.4 (42.8, 46.0)
CVD, cardiovascular disease; EPO, erythropoietin; ESRD, end-stage renal disease; CI, class interval; MI, myocardial infarction.
Combined MI includes fatal and non-fatal MI events.
aCI, confidence interval.
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factor for recurrent MI, whereas belonging to a racial/ethnic
minority group was associated with a lower risk of non-fatal
and combined fatal and non-fatal MI compared with
Caucasians. Racial/ethnic differences in risk were similar
among those with and without prevalent CVD diagnosed at
the time of initiation of dialysis.
Because African Americans are less likely to be diagnosed
with cardiovascular events prospectively in the general
population, we felt that it was important to also explore
cardiac-related deaths as a combined outcome with non-fatal
MI. Studies have shown that African Americans have been
more likely to present with out of hospital cardiac arrests
than Caucasians and less likely to have cardiac procedures
ordered compared with Caucasians,6–12 although this may be
negligible in the dialysis population.13 We found that for
both non-fatal and combined MI, African Americans and
other minority groups had a lower risk of incident MI events
compared to Caucasians regardless of which combined
end-point was examined.
Recently, limited studies have evaluated racial/ethnic
differences in the risk of incident MI and MI-associated
mortality in a national dialysis population. Trespalacios4
evaluated the risk of acute coronary syndrome in the USRDS
Dialysis Morbidity and Mortality Study, Wave II, and found
that African Americans were 46% less likely to have prevalent
CVD; however, the risk of incident cardiac event was not
reported separately by race or ethnicity. In a report that used
combined data from CMS and the USRDS, Ganesh14
evaluated all-cause mortality in hemodialysis and peritoneal
dialysis patients, and found that Caucasians had a 1.25-fold
greater risk of mortality than non-white subjects (aRR¼ 1.25,
95% CI: 1.22–1.29); however, individual racial and ethnic
groups risk of cardiac-related mortality was not assessed.
Finally, utilizing USRDS data, Parekh et al5 also found that
African Americans had a lower incidence of atherosclerosis
events, results that are similar to ours except that their final
outcome included all causes of atherosclerotic disease, such
as coronary artery disease and peripheral vascular disease.5
Although the current study results are robust, results from
studies evaluating racial and ethnic differences in incident MI
in populations with earlier stages of chronic kidney disease
before the initiation of dialysis have been inconsistent. In a
meta-analysis that combined four community cohort studies,
Weiner3 reported that African Americans had a 1.8-fold
Table 3 | Relative risk of combined non-fatal and fatal MI adjusted for baseline covariatesa
Prevalent CVD No prevalent CVD
Covariate Relative risk (95% CI) P-value Relative risk (95% CI) P-value
Gender (women vs men) 0.88 (0.84, 0.92) o0.001 0.87 (0.82, 0.91) o0.001
Age per 10 years 1.19 (1.17, 1.21) o0.001 1.32 (1.30, 1.35) o0.001
Race
Caucasian 1.0 — 1.0 —
African American 0.65 (0.62, 0.68) o0.001 0.67 (0.64, 0.71) o0.001
Asian American 0.74 (0.66, 0.83) o0.001 0.72 (0.63, 0.81) o0.001
Hispanic 0.72 (0.68, 0.77) o0.001 0.65 (0.60, 0.70) o0.001
Other 0.65 (0.56, 0.75) o0.001 0.58 (0.49, 0.70) o0.001
Cause of ESRD
Diabetes 1.0 — 1.0 —
Hypertension 0.88 (0.84, 0.92) o0.001 0.72 (0.68, 0.76) o0.001
Glomerulonephritis 0.75 (0.69, 0.81) o0.001 0.49 (0.45, 0.53) o0.001
Other 0.78 (0.73, 0.82) o0.001 0.50 (0.47, 0.54) o0.001
Modality
Hemodialysis 1.0 — 1.0 —
Peritoneal dialysis 0.98 (0.92, 1.05) 0.588 1.06 (0.99, 1.15) 0.099
Transplant 0.47 (0.38, 0.59) o0.001 0.41 (0.35, 0.48) o0.001
Wait list 0.68 (0.59, 0.80) o0.001 0.68 (0.60, 0.76) o0.001
Baseline
Hypertension 0.98 (0.93, 1.02) 0.309 0.94 (0.89, 0.99) 0.011
Peripheral vascular disease 1.21 (1.16, 1.26) o0.001 1.27 (1.18, 1.37) o0.001
Inability to ambulate 1.00 (0.93, 1.08) 0.961 1.05 (0.92, 1.20) 0.453
EPO use 0.89 (0.86, 0.93) o0.001 0.94 (0.89, 0.99) 0.015
Albumin (g/dl) 0.93 (0.90, 0.96) o0.001 0.89 (0.86, 0.92) o0.001
Hemoglobin (g/dl) 1.04 (1.02, 1.05) o0.001 1.03 (1.02, 1.05) o0.001
BUN (mg/dl) 1.00 (1.00, 1.00) 0.828 1.00 (1.00, 1.00) 0.395
Creatinine clearance (ml/min) 1.00 (0.99, 1.00) 0.06 1.00 (0.99, 1.00) 0.128
Height per 10 cm 0.99 (0.97, 1.00) 0.129 0.99 (0.97, 1.01) 0.171
Weight per 10 kg 0.96 (0.95, 0.97) o0.001 0.96 (0.95, 0.97) o0.001
BUN, blood urea nitrogen; CI, class interval; CVD, cardiovascular disease; EPO, erythropoietin; ESRD, end-stage renal disease; MI, myocardial infarction.
aAfter restricted to patients without missing covariates, N=81 106 and 100 998 for prevalent CVD and no prevalent CVD respectively.
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greater risk of a combined cardiac/stroke/death outcome than
Caucasians, and that African Americans with chronic kidney
disease had a greater risk of having an MI than white subjects.
Conversely, using data from a large managed care system
population with diabetes, Karter15 reported that African
Americans and other minority populations were less likely to
have an incident MI, but were as likely to be diagnosed with
congestive heart failure compared with Caucasians. In
addition, we previously reported that diabetic African-
American veterans and other minority populations were less
likely to be diagnosed with prevalent CVD and had a slight
survival advantage compared with Caucasians.16 Differences
in studies may be related to access to preventive health care
before initiating renal replacement therapy, although further
research is necessary in this regard. Alternatively, the disparity
observed among ESRD patients may be contingent upon the
ability of patients to survive the later stages of chronic kidney
disease to initiate renal replacement therapy, and perhaps only
the healthiest minority patients survive to initiate dialysis;
thus, minorities may have a perceived lower incidence of MI
than Caucasians owing to a healthy cohort effect.
Mechanisms for these observed differences in the risk
of MI and MI-related deaths by race/ethnicity are speculative
at best. Khurana17 reported that African-American women
had similar coronary calcium scores compared to Caucasian
women, even though African-American women in the study
had a greater number of CVD risk factors than Caucasian
women.17 Conversely, Bild et al.18 found no difference in
coronary calcification among participants of the Coronary
Artery Risk Development in Young Adults study,18 whereas
other investigators reported that African Americans had
lower coronary calcium stores than white subjects in cross-
sectional analyses.19,20 The long-term risk of incident CVD,
however, was not assessed. In a study that evaluated racial
disparities in the rates of revascularization and cardiovascular
procedures, Barnhart21 found that African Americans were as
likely to survive as Caucasians in the absence of cardio-
vascular revascularization. In addition, using data from the
Myocardial Infarction Triage and Intervention registry,
Maynard showed that when African Americans obtained
coronary artery disease catheterization as frequently as
Caucasians, African Americans had better survival.12
Factors thought to contribute to racial/ethnic disparities in
the incidence of MI include lack of access to medical care,22,23
low socio-economic status,22,23 increased prevalence of risk
factors such as smoking, hypertension, obesity, and dia-
betes,3,23 lack of access to cardiovascular associated procedures
or racial discrimination in referral for cardiac-related proce-
dures,24 or misclassification of CVD diagnoses. As African
Americans and other minority groups are more likely to have
chronic kidney disease, one could hypothesize that racial/
ethnic minorities might be at greater risk for death before the
initiation of dialysis, although this hypothesis was not
evaluated in recent studies using Medicare data.25 This
assertion could be true in populations that do not have access
to care but has shown not to be the case in populations with
access to care before initiation of dialysis such as the veterans.16
In addition, differential receipt of a diagnosis of MI or cardiac-
related procedures could explain some of the differences found
in the current study; however, utilizing USRDS data, Daumit
et al.13 found that once dialysis was initiated, racial disparities
in receipt of cardiac procedures was negligible. Although
controversial, possible genetic or biologic differences in CVD
susceptibility,26 or other potential biologic differences such as
differences in parathyroid hormone and calcium levels,27 blood
pressure control, or cytokine polymorphisms28–31 may exist
and could contribute to racial/ethnic differences in MI rates.
Although the current study is strengthened by the
evaluation of a national cohort of incident dialysis patients,
there are certain limitations that deserve discussion. Because
of limitations of the USRDS database, this study could not
evaluate the potential effect of differences in dialysis
prescription, current medication use, ongoing nutritional
status,32 dialysis adequacy, dialysis compliance, current EPO
use or hemoglobin level changes over time, smoking, or
dyslipidemia, factors that are all known to affect the risk of
CVD in the dialysis population. However, the study was able
to adjust for baseline characteristics, which included an
assessment of baseline nutritional status (albumin), anemia
(hemoglobin), predialysis EPO use, and diagnosis of hyper-
tension, all of which were not found to contribute significantly
to racial/ethnic differences in the risk of combined MI. An
additional limitation was that race and ethnicity were not
known for a very small number of patients, 11 (0.01%);
however, this number was so small that it did not have any
effect on the final outcomes. Further, because the USRDS only
records hospitalization data from those patients with
Medicare as the primary insurance, there is limited ability
to generalize the results to patients with private insurance.
Finally, we were not able to adjust for factors that may be
potentially related to health disparities, such as lack of access
to medical care before initiation of dialysis, worse socio-
economic status, and misclassification of CVD diagnosis
before initiation of dialysis. However, similar results were
found for those with and without prevalent CVD, adjusted for
EPO use (potentially a surrogate marker for those with prior
access to health care), which makes the contribution of these
variables to a change in the overall findings less likely.
We conclude that ESRD patients with prevalent CVD
have a much greater risk of incident non-fatal and combined
MI, and that belonging to a racial and ethnic minority
group is associated with lower rates of non-fatal and fatal
MI compared to Caucasians, after adjustment for time on
dialysis, dialysis modality, age, gender, placement on the
transplant waiting list, and baseline characteristics. Further
research is warranted to determine biologic or environmental
factors that may play a role in CVD among ESRD patients.
MATERIALS AND METHODS
Data source
Data for the analyses were obtained from the 2003 USRDS database
release. Details regarding the structure and data collection methods
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have been reported elsewhere.33 Briefly, the USRDS records
demographic and clinical information on all patients with ESRD
for whom renal replacement therapy was initiated and who have
survived more than 90 days from the start of therapy. Baseline
data were abstracted from the ESRD Medical Evidence Reports
(Centers for Medicare and Medicaid Services Form 2728), the
United Network for Organ Services transplant records, ESRD
Network Census reports, and death notification reports. Among
those patients for whom Medicare was the primary or secondary
insurance provider, hospitalization data were obtained from
Medicare billing records.
Study population
All incident dialysis patients greater than 18 years of age but less
than 110 years who were enrolled in the USRDS between January 1,
1995 and 31 December 2000 for whom Medicare was the primary
insurance were considered for this analysis. Medicaid patients were
included in the cohort as well, as Medicaid and Medicare patients
are listed together as a single choice in the USRDS insurance payer
variable. Because USRDS data were incomplete for patients after
31 December 2000 owing to billing issues, data were censored after
this date. Patients with an indication of renal transplantation or
death before initiation of renal replacement therapy were excluded.
Patients were considered at risk 90 days after initiation of renal
replacement therapy until the first of the following: death, lost-to-
follow-up, loss of Medicare as primary insurance coverage, end of
study (31 December 2000), or 3 years after the date of transplant.
Owing to the non-uniformity of transplantation data and the
potential loss of Medicare data for thoseo65 years after 3 years of a
successful transplantation, all transplant patients were censored 3
years after the transplantation date.
Determination of MI
An incident MI was characterized as being non-fatal (hospitaliza-
tion) or fatal (death owing to MI). Using hospitalization data
obtained from the USRDS billing records hospital standard analysis
file (HOSP1.SAF and HOSP2.SAF), a non-fatal MI was defined as
a primary or secondary International Classification of Diseases, Ninth
Revision (ICD-9) code34 consistent with MI (410.xx). The first date
of hospitalization was considered the first date of non-fatal MI.
Using the cause of death codes from the patients’ standard analysis
file, fatal MI was defined as any cause of death that was secondary to
an MI, and included all codes for ‘MI, acute’. Incident non-fatal and
fatal MI events (combined MI) were combined for the final
outcome.
Exposures
The primary risk factor of interest identified a priori was race or
ethnicity. Patients were classified by race/ethnicity into the
categories Caucasian, African American, Asian American, Hispanic
and other, which were based on data from the USRDS standard
analysis file and medical evidence form (Form 2728) obtained at the
initiation of renal replacement therapy. Those included in the ‘other’
racial category were of Native American ethnicity or any other race/
ethnicity not included above. Secondary predictors of interest
included gender, age, primary cause of ESRD, renal replacement
modality (peritoneal dialysis, hemodialysis, or transplant), and
placement on the transplant waiting list. Other covariates of interest
abstracted from the medical evidence form included the following
baseline covariates: ability to ambulate, EPO use before renal
replacement therapy, albumin (g/dl), hemoglobin (g/dl), blood urea
nitrogen (BUN) (mg/dl), creatinine (mg/dl), height (cm), and
weight (kg). Baseline laboratory data were only considered for
patients who had a laboratory test value recorded within 1 year of
initiating renal replacement therapy. Prevalent CVD was defined
by any indication of ischemic heart disease, MI, cardiac arrest,
or congestive heart failure at baseline on the Medical Evidence
Form 2728.
Statistical analysis
Incidence rates for non-fatal and combined MI were calculated as
the observed number of events per total patient time at risk. Owing
to a potential disparity in reporting of non-fatal MI among
minorities and the inability to distinguish between patients with and
without an MI resulting in immediate death, both non-fatal and
combined non-fatal and fatal MI outcomes were investigated.7–9
Non-fatal and combined MI event rates were calculated by the total
number of events divided by the number of person-years at risk;
confidence intervals were determined using a normal approximation
and square-root transformation.35 Patients were considered at risk at
the start of Medicare coverage within 90 days of initiation of renal
replacement therapy to the time of censoring. Cox proportional
hazards models36 using time-dependent covariates and robust
variance estimation were used to analyze the association between
race/ethnicity and the risk of incident MI separately for subgroups
defined by prevalent CVD. Treatment status (hemodialysis,
peritoneal dialysis, and transplant) and placement on the transplant
waiting list were modeled as time-dependent covariates. Transplant-
ation, however, was analyzed according to an ‘intention-to-treat’
principle. Thus, transplanted patients were analyzed in the
transplantation group throughout the remainder of follow-up
regardless of subsequent changes in transplantation status. Because
of potential confounding and because those with prevalent CVD are
known to be at risk for a subsequent cardiac event in the general
population, we conducted separate analyses for those with and
without prevalent CVD. All statistical analyses were performed using
SAS version 8.2 (SAS Institute Inc., Cary, NC,USA) and S-Plus
version 6.1 (Insightful Inc., Seattle, WA, USA).
ACKNOWLEDGMENTS
The data reported here have been supplied by the USRDS. The
interpretation and reporting of these data are the responsibility of
the author(s) and in no way should be seen as an official policy or
interpretation of the US government. This work was supported by
American Diabetes Association Career Development Award and a
Robert Wood Johnson Harold Amos Medical Faculty Development
Fellowship, which currently support Dr Bessie Young.
REFERENCES
1. USRDS 2005 Annual Data Report. Atlas of End-Stage Renal Disease in the
United States. National Institutes of Health, National Institute of Diabetes
and Digestive and Kidney Diseases: Bethesda, MD 2002.
2. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of
cardiovascular disease in chronic renal disease: what do we know? What
do we need to learn? Where do we go from here? National Kidney
Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;
32: 853–906.
3. Weiner DE, Tighiouart H, Amin MG et al. Chronic kidney disease as a risk
factor for cardiovascular disease and all-cause mortality: a pooled analysis
of community-based studies. J Am Soc Nephrol 2004; 15: 1307–1315.
4. Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC. Incident acute
coronary syndromes in chronic dialysis patients in the United States.
Kidney Int 2002; 62: 1799–1805.
5. Parekh RS, Zhang L, Fivush BA, Klag MJ. Incidence of atherosclerosis
by race in the Dialysis Morbidity and Mortality Study: a sample of the
US ESRD population. J Am Soc Nephrol 2005; 16: 1420–1426.
Kidney International (2006) 69, 1691–1698 1697
BA Young et al.: Myocardial infarction in ESRD patients o r i g i n a l a r t i c l e
6. Conigliaro J, Whittle J, Good CB et al. Understanding racial variation in the
use of coronary revascularization procedures: the role of clinical factors.
Arch Intern Med 2000; 160: 1329–1335.
7. Wenneker MB, Epstein AM. Racial inequalities in the use of procedures
for patients with ischemic heart disease in Massachusetts. JAMA 1989;
261: 253–257.
8. Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial differences in the use
of invasive cardiovascular procedures in the Department of Veterans
Affairs Medical System. N Engl J Med 1993; 329: 621–627.
9. Weitzman S, Cooper L, Chambless L et al. Gender, racial, and geographic
differences in the performance of cardiac diagnostic and therapeutic
procedures for hospitalized acute myocardial infarction in four states.
Am J Cardiol 1997; 79: 722–726.
10. Whittle J, Conigliaro J, Good CB, Joswiak M. Do patient preferences
contribute to racial differences in cardiovascular procedure use?
J Gen Intern Med 1997; 12: 267–273.
11. Petersen LA, Wright SM, Peterson ED, Daley J. Impact of race on cardiac
care and outcomes in veterans with acute myocardial infarction.
Med Care 2002; 40: 86–96.
12. Maynard C, Every NR, Martin JS, Weaver WD. Long-term implications
of racial differences in the use of revascularization procedures (the
Myocardial Infarction Triage and Intervention registry). Am Heart J 1997;
133: 656–662.
13. Daumit GL, Hermann JA, Coresh J, Powe NR. Use of cardiovascular
procedures among black persons and white persons: a 7-year nationwide
study in patients with renal disease. Ann Intern Med 1999; 130: 173–182.
14. Ganesh SK, Hulbert-Shearon T, Port FK et al. Mortality differences by
dialysis modality among incident ESRD patients with and without
coronary artery disease. J Am Soc Nephrol 2003; 14: 415–424.
15. Karter AJ, Ferrara A, Liu JY et al. Ethnic disparities in diabetic
complications in an insured population. JAMA 2002; 287: 2519–2527.
16. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic
nephropathy, cardiovascular disease, and mortality in a national
population of veterans. Diabetes Care 2003; 26: 2392–2399.
17. Khurana C, Rosenbaum CG, Howard BV et al. Coronary artery calcification
in black women and white women. Am Heart J 2003; 145: 724–729.
18. Bild DE, Folsom AR, Lowe LP et al. Prevalence and correlates of coronary
calcification in black and white young adults: the Coronary Artery Risk
Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc
Biol 2001; 21: 852–857.
19. Newman AB, Naydeck BL, Sutton-Tyrrell K et al. Coronary artery
calcification in older adults to age 99: prevalence and risk factors.
Circulation 2001; 104: 2679–2684.
20. Lee TC, O’Malley PG, Feuerstein I, Taylor AJ. The prevalence and severity
of coronary artery calcification on coronary artery computed tomography
in black and white subjects. J Am Coll Cardiol 2003; 41: 39–44.
21. Barnhart JM, Fang J, Alderman MH. Differential use of coronary
revascularization and hospital mortality following acute myocardial
infarction. Arch Intern Med 2003; 163: 461–466.
22. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal
disease in men. N Engl J Med 1996; 334: 13–18.
23. Klag MJ, Whelton PK, Randall BL et al. End-stage renal disease in
African-American and white men 16 year MRFIT findings. JAMA 1997;
277: 1293–1298.
24. Schulman KA, Berlin JA, Harless W et al. The effect of race and sex on
physicians’ recommendations for cardiac catheterization. N Engl J Med
1999; 340: 618–626.
25. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk
for cardiovascular disease, renal replacement, and death in the
United States Medicare population, 1998 to 1999. J Am Soc Nephrol
2005; 16: 489–495.
26. Langefeld CD, Beck SR, Bowden DW et al. Heritability of GFR and
albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis
2004; 43: 796–800.
27. De Boer IH, Gorodetskaya I, Young B et al. The severity of secondary
hyperparathyroidism in chronic renal insufficiency is GFR-dependent,
race-dependent, and associated with cardiovascular disease. J Am Soc
Nephrol 2002; 13: 2762–2769.
28. Freedman BI, Bowden DW. The role of genetic factors in the development
of end-stage renal disease. Curr Opin Nephrol Hypertens 1995; 4:
230–234.
29. Freedman BI, Wilson CH, Spray BJ et al. Familial clustering of end-stage
renal disease in blacks with lupus nephritis. Am J Kidney Dis 1997; 29:
729–732.
30. Freedman BI, Yu H, Spray BJ et al. Genetic linkage analysis of growth
factor loci and end-stage renal disease in African Americans. Kidney Int
1997; 51: 819–825.
31. Freedman BI, Bowden DW, Rich SS, Appel RG. Genetic initiation of
hypertensive and diabetic nephropathy. Am J Hypertens 1998; 11:
251–257.
32. Fung F, Sherrard DJ, Gillen DL et al. Increased risk for cardiovascular
mortality among malnourished end-stage renal disease patients.
Am J Kidney Dis 2002; 40: 307–314.
33. Anonymous. U.S. Renal Data System: excerpts from the USRDS 2000
Annual Data Report: atlas of end-stage renal disease in the United States.
Am J Kidney Dis 2000; 36: S1–S238.
34. Anonymous. Physician ICD-9-CM. Medicode Publications: Salt Lake City,
UT, 1999.
35. Fisher L, Van Belle G. Biostatistics: A Methodology for the Health Sciences.
Wiley New York, NY, 1993.
36. Cox D. Regression models and life tables. J R Stat Soc B 1972; 34:
187–220.
1698 Kidney International (2006) 69, 1691–1698
o r i g i n a l a r t i c l e BA Young et al.: Myocardial infarction in ESRD patients
